Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.

Joop De Langen, Justine Leonie Kuiper, Erik Thunnissen, Sayed M. S. Hashemi, Kim Monkhorst, Egbert F. Smit

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of clinical oncology
Publication statusPublished - 20 May 2017

Cite this